Can Boston Scientific Surpass Its Earnings Estimates in 3Q17?
BSX’s EPS estimate for 3Q17 represents YoY (year-over-year) growth in the range of 9%–16%. In 2Q17, Boston Scientific registered EPS growth of 18.5% YoY.
Boston Scientific’s (BSX) 3Q17 revenues are expected to come in at $2.21 billion, representing YoY (year-over-year) growth of ~4.8%.
BSX stock has been performing well recently, and investor confidence appears to have ridden on innovative product launches and strong 2Q17 results.
On October 13, 2017, in a Reuters survey comprising 17 brokerages, six (~35.3%) analysts rated Baxter International as a “buy.”
On October 5, 2017, Baxter International (BAX) announced the voluntary recall of a shipment from a lot of Intralipid 20% IV Fat Emulsion, 100 mL. This lot was distributed from August 11 to August 31, 2017.
Edwards Lifesciences (EW) was trading at a high of $110.60 on October 12, 2017. The stock closed the day at $110.20.
As of October 13, 2017, according to a Reuters survey consisting of 22 brokerage firms, 77.3% of the firms rated Edwards Lifesciences a “buy.”
According to Wall Street analysts’ estimates, Edwards Lifesciences’ fiscal 3Q17 EPS is expected to be $0.86.
According to Wall Street analysts’ estimates for 3Q17, Edwards Lifesciences is expected to have revenues of $8.3 billion, a YoY (year-over-year) sales growth of 12.5%.
Edwards Lifesciences (EW) has scheduled its 3Q17 earnings release for October 24, 2017. This leading player in the artificial heart valves market has been gaining momentum and trading near its 52-week high.
According to analysts’ estimates, Intuitive Surgical is expected to post 3Q17 adjusted diluted EPS of $1.99.
Johnson & Johnson’s (JNJ) medical device business has been restructuring in order to focus on higher growth areas with potential expansion opportunities.
On October 12, 2017, Johnson & Johnson’s (JNJ) medical device subsidiary, Depuy Synthes, announced the launch of the company’s new TFNA Augmentation system in the United States.
Johnson & Johnson (JNJ) registered revenues of $18.8 billion, a YoY (year-over-year) increase of around 1.6% in 2Q17.
Johnson & Johnson (JNJ) will announce its 3Q17 earnings results on October 17, 2017.
According to recent Wall Street analysts’ estimates, Intuitive Surgical is expected to report revenues of $753.2 million in 3Q17. That represents a YoY sales growth of 10.3%.
Intuitive Surgical (ISRG) is set to announce its 3Q17 earnings results on October 19, 2017. Over the past few weeks, ISRG stock has risen to new highs.
In 3Q17, the Established Pharmaceuticals segment of Abbott Laboratories is expected to report high double-digit operational sales growth.
The 3Q17 EPS estimate for Abbott Laboratories is $0.65. The company has provided an EPS guidance range of $0.64–$0.66 for 3Q17.
Analysts expect Abbott Laboratories to report 3Q17 revenues of ~$6.7 billion, representing a YoY (year-over-year) growth of ~26.7%.